Issue 1 2021

14 CEO MONTHLY / ISSUE 1 2021 , Nov20222 Data-Driven Diagnostics Are CEO’s Core Competency Lung diseases have been placed front and centre of the medical community in the last year and a half, given the emergence of COVID-19 and its various impacts on breathing difficulties. Understanding lung disease is key to beating them, and that is part of the work carried out by Biodesix Inc., a leading data-driven diagnostic solutions company helping to answer critical clinical questions. The firm is also home toMr Scott Hutton, recipient of the title of CEO of the Year, 2020 – The USA. Join us as we highlight Mr Hutton’s personal and professional success, as well as take a closer look at what Biodesix Inc. has to offer as a business. When it comes to tackling any new lung disease, there are a great many things to consider and query before real strides can be made. Physicians, researchers, and biopharmaceutical companies alike all have to consider critically-important clinical questions that will help to shine a light on how a new disease operates, and what systems it targets when it infects a new person. Take COVID-19 for example. Before vaccines became a reality, there was a wealth of research and careful consideration to understand the virus and how it operates. It is this kind of research and understanding that is the primary focus of the work carried out by Biodesix Inc.. Since its inception, the firm has been a leading data-driven diagnostic solutions company that has sought to help answer critical clinical questions faced by physicians, researchers, biopharmaceutical companies, and medical professionals when dealing with lung disease. In seeking to answer these questions, the mission of Biodesix Inc. becomes increasingly clear: to improve every patient’s lung disease care by empowering physicians with swift, comprehensive, and actionable insights. Understanding how diseases and infections work is imperative to understanding how to beat them and give a patient their life back. Biodesix Inc.’s vision is to be a trusted partner that the world relies on for data- driven diagnostic solutions in lung disease and beyond. In working to achieve this mission and see this vision become a reality, Biodesix Inc. operates in several key areas. These include leveraging a technology- agnostic approach and a proprietary AI platform to provide a holistic view of each patient’s disease state, solving complex diagnostic challenges in lung disease, and believing that every patient deserves a personalized approach to improving their care. Taking care of those fighting against a lung disease is no easy feat, but Biodesix Inc. always strives to be a trusted partner with end-to-end diagnostic solutions for every eventuality. Technology is key in this fight and it has certainly come a long way, even just in the last few years. Advancements are being made all time, but Biodesix Inc.’s core belief is that no single technology can answer all diagnostic research questions that may arise. Working alongside biopharmaceutical partners, the firm employs a personalized and integrated approach to technology-agnostic service delivery. Uncovering the wealth of information around disease biology requires access to many technologies, and Biodesix Inc. works with many different technologies, or “omics” to ensure that the patient gets the best care imaginable. Just some of these technologies allow the firm and its biopharmaceutical partners to carry out diagnostic research to uncover novel insights about tumour biology and the patient’s immune response to cancer for biopharmaceutical therapeutics in clinical developments. Using technology to help uncover new insights and information about a patient’s status can not only help them with understanding the disease, but also the care plan. The blood tests carriedout by Biodesix Inc. are helping to provide physicians with swiftand actionable biomarker results to support an individualized and personalized care plan like no other. Overseeing all of this outstanding work is the recipient of today’s title of CEO of the Year, 2020 – The USA: Mr Scott Hutton. Mr Hutton has served diligently as the President, Chief Executive Officer, and Director of Biodesix Inc. since January 2020, and it has been quite the first year for him, as he led the company through an Initial Public Offering (IPO) and listed on NASDAQ the morning of October 26th, 2020. Scott Hutton accomplished this in the face of a global pandemic and the most tumultuous election year in US history. Prior to holding the role of CEO at the firm, Mr Hutton had previously held the role of Chief Operating Officer from March 2018 to December 2019. On top of this, the outstanding Mr Hutton has served on the board of Eximis Surgical since February 2018,was an Observer on the board of Aqueduct Critical Care from September 2014 to January 2017, was an Observer on the board of Visualase from October